Product information and disease descriptionProduct descriptionProduct information
Special populations
7 evidence topics · 10 sources
Hepatic impairment: single-dose pharmacokinetic study design
Hepatic and renal function thresholds for trial eligibility
Age: eligibility and enrolled age ranges
| Population | Age (years), median (min-max) |
|---|---|
| Efficacy population, varegacestat (RINGSIDE Parts A and B), N = 121 | “40 (18-72)” |
| Efficacy population, placebo (RINGSIDE Part B), N = 77 | “39 (20-69)” |
| Safety population, varegacestat (CA002-001 and RINGSIDE), N = 157 | “45 (18-84)” |